Rupatadine for mild to moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study is testing if the allergy medicine rupatadine can help calm inflammation in people with mild to moderate ulcerative colitis. It is for people who are not already on strong UC treatments and want to try a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with mild to moderate ulcerative colitis.
- You are not pregnant or breastfeeding.
- You do not have colorectal cancer, a severe UC flare, or a known allergy to the study drug.
- You are not currently taking steroids, immunosuppressants, or biologic therapies for your UC.
- You do not have a history of alcohol or drug addiction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.
This trial tests if a medication called nitazoxanide can help people with mild to moderate ulcerative colitis (UC). It may be a treatment option for those not already on strong UC medications.
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.